Kiniksa Pharmaceuticals International, plc (KNSA) › Cash & EquivalentsKiniksa Pharmaceuticals International, plc (KNSA) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2017-12-31: $45.55M2018-12-31: $71.98M2019-12-31: $46.93M2020-12-31: $114.04M2021-12-31: $122.47M2022-12-31: $122.72M2023-12-31: $107.95M2024-12-31: $183.58M2025-12-31: $165.60M$165.60M2017-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$165.60M-9.8%2026-02-24Balance as of period end2024-12-31$183.58M+70.1%2026-02-24Balance as of period end2023-12-31$107.95M-12.0%2025-02-25Balance as of period end2022-12-31$122.72M+0.2%2024-02-28Balance as of period end2021-12-31$122.47M+7.4%2023-03-02Balance as of period end2020-12-31$114.04M+143.0%2022-02-24Balance as of period end2019-12-31$46.93M-34.8%2021-02-25Balance as of period end2018-12-31$71.98M+58.0%2020-03-05Balance as of period end2017-12-31$45.55M—2019-03-12Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)